Haemonetics Corporation (HAE) is a Medical - Instruments & Supplies company in the Healthcare sector, currently trading at $60.48. It has a SharesGrow Score of 77/100, indicating a strong investment profile with 6 out of 7 criteria passed.
SharesGrow calculates the intrinsic value of HAE = $127.27 (+110.4% from the current price, the stock appears undervalued). Analyst consensus target is HAE = $87 (+43.2% upside).
Valuation: HAE trades at a trailing Price-to-Earnings (P/E) of 15.6 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 1.39.
Financials: revenue is $1.4B, +5.3%/yr average growth. Net income is $168M, growing at +14.8%/yr. Net profit margin is 12.3% (healthy). Gross margin is 55% (+2.4 pp trend).
Balance sheet: total debt is $304M against $821M equity (Debt-to-Equity (D/E) ratio 0.37, conservative). Current ratio is 1.62 (strong liquidity). Debt-to-assets is 12.4%. Total assets: $2.5B.
Analyst outlook: 10 / 20 analysts rate HAE as buy (50%) — moderate consensus.
SharesGrow 7-Criteria breakdown: Value 70/100 (Pass), Growth 73/100 (Pass), Past 100/100 (Pass), Health 100/100 (Pass), Moat 74/100 (Pass), Future 64/100 (Pass), Income 55/100 (Partial).
